nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

05.11.2018 | short review

The ASCO 2018 annual meeting: update on the adjuvant treatment of early breast cancer

verfasst von: Dr. Clemens Dormann, PD Dr. Karl J. Aichberger

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Summary

At this year’s American Society of Clinical Oncology (ASCO) annual meeting two large phase 3 trials, the ABCSG-18 and the D‑CARE study, analysed the effects of adjuvant denosumab in breast cancer patients and reported different outcomes. Another phase 3 study, the ASTRRA trial, investigated the use of adjuvant ovarian function suppression (OFS) in high-risk premenopausal patients. This trial confirmed the benefit of OFS similar to the results of the already published SOFT/TEXT trials but raises some crucial questions on the optimal duration of OFS in these patients. The results of the SOFT/TEXT trials were also updated at this meeting.

Vorheriger Artikel ASCO 2018 NSCLC highlights—combination therapy is key

Nächster Artikel ASCO 2018 highlights: metastatic breast cancer

Early Breast Cancer Trialists’ Collaborative Group. (EBCTCG). Adjuvant bisphosphonate treatment in early breast cancer: Meta-analyses of individual patient data from randomised trials. Lancet. 2015;386:1353–61. https://doi.org/10.1016/S0140-6736(15)60908-4.CrossRef

Dhesy-Thind S, Fletcher GG, Blanchette PS, et al. Use of Adjuvant Bisphosphonates and other Bone-modifying agents in breast cancer: a cancer care ontario and American society of clinical oncology clinical practice guideline. J Clin Oncol. 2017;35(18):2062–81. https://doi.org/10.1200/JCO.2016.70.7257.CrossRefPubMed

Gnant M, Pfeiler G, Steger GG, et al. Adjuvant denosumab in early breast cancer: Disease-free survival analysis of 3,425 postmenopausal patients in the ABCSG-18 trial. J Clin Oncol. 2018;36(15_suppl):500–500. https://doi.org/10.1200/JCO.2018.36.15_suppl.500.CrossRef

Coleman RE, Finkelstein D, Barrios CH, et al. Adjuvant denosumab in early breast cancer: first results from the international multicenter randomized phase III placebo controlled D‑CARE study. J Clin Oncol. 2018;36(15_suppl):501–501. https://doi.org/10.1200/JCO.2018.36.15_suppl.501.CrossRef

Gnant M, Pfeiler G, Dubsky PC, et al. Adjuvant denosumab in breast cancer (ABCSG-18): a multicentre, randomised, double-blind, placebo-controlled trial. Lancet. 2015;386:433–43. https://doi.org/10.1016/s0140-6736(15)60995-3.CrossRefPubMed

Pagani O, Regan MM, Walley BA, et al. Adjuvant Exemestane with ovarian suppression in Premenopausal breast cancer. N Engl J Med. 2014;371:107–18. https://doi.org/10.1056/NEJMoa1404037.CrossRefPubMedPubMedCentral

Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression in Premenopausal breast cancer. N Engl J Med. 2015;372:436–46. https://doi.org/10.1056/NEJMoa1412379.CrossRefPubMed

Regan MM, Francis PA, Pagani O, et al. Absolute benefit of Adjuvant endocrine therapies for Premenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2‑negative early breast cancer: TEXT and SOFT trials. J Clin Oncol. 2016;34:2221–31. https://doi.org/10.1200/JCO.2015.64.3171.CrossRefPubMedPubMedCentral

Francis PA, Pagani O, Fleming GF, et al. Tailoring Adjuvant endocrine therapy for Premenopausal breast cancer. N Engl J Med. 2018;379:122–37. https://doi.org/10.1056/NEJMoa1803164.CrossRefPubMedPubMedCentral

10.

Regan MM, Francis PA, Pagani O, et al. Absolute improvements in freedom from distant recurrence with adjuvant endocrine therapies for premenopausal women with hormone receptor-positive (HR+) her2-negative breast cancer (BC): results from TEXT and SOFT. J Clin Oncol. 2018;36(15_suppl):503–503. https://doi.org/10.1200/JCO.2018.36.15_suppl.503.CrossRef

11.

Noh WC, Lee JW, Nam SJ, et al. Role of adding ovarian function suppression to tamoxifen in young women with hormone-sensitive breast cancer who remain premenopausal or resume menstruation after chemotherapy: the ASTRRA study. J Clin Oncol. 2018;36(15_suppl):502–502. https://doi.org/10.1200/JCO.2018.36.15_suppl.502.CrossRef

Titel: The ASCO 2018 annual meeting: update on the adjuvant treatment of early breast cancer
verfasst von: Dr. Clemens Dormann
PD Dr. Karl J. Aichberger
Publikationsdatum: 05.11.2018
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2018
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-018-0448-3

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Personalized prostate cancer diagnosis and treatment—are we ready?

Educational no. 3: Cytogenetic analysis (CA)

ASCO update 2018: upper gastrointestinal cancer

ASCO 2018: highlights of urothelial cancer and prostate cancer

The microbiome of the prostate

Economic analysis of biomarker-based anti-EGFR therapies in metastatic colorectal cancer in the Austrian context